We know gout is among the many comorbidities that increase the risk of cardiovascular disease (CVD). In 2018, the cardiovascular safety of febuxostat and allopurinol in patients with gout and cardiovascular morbidities (CARES) trial concluded that febuxostat was non-inferior to allopurinol. BUT, two of the secondary endpoints were very concerning. Febuxostat was inferior to allopurinol in terms of cardiovascular death and all-cause mortality. Many clinicians were left wondering whether febuxostat was cardiotoxic …. or conversely, perhaps allopurinol was cardioprotective. Will another cardiovascular outcome trial provide greater clarity to guide clinical practice?
Guest Authors: Sophia Dietrich, PharmD and Michael W. Nagy, PharmD, BCACP
Guest Panelist: Dawn Fuke, PharmD, BCPS
Music by Good Talk
An Incli-ng of Benefit? Efficacy and Safety of Inclisiran for Elevated LDL
Will Riva Be Defeated By It’s (Long-Standing) Nemesis, Apixa?
Should Penicillin Allergy Skin Testing be a Thing of the PAST?
Does Long-Term Proton Pump Inhibitor Use Pump Up Your Risk of Adverse Effects?
Is the Grass Really Greener? Cognitive Function After Discontinuation of Cannabis
A CLEAN Sweep: Getting Rid of the Medication Cost Barrier
Should Bedtime be Med-Time for Hypertension?
Let’s COLCOT to the Chase: Colchicine for Secondary Prevention of CV Events
Don’t Let Numbers Fool You: Levothyroxine Isn’t a Cure-all
Age is Just a Number: Discontinue Statins with Care
A Cause for a PAUSE: Evaluating a Standardized Perioperative DOAC Management Protocol
Who CARES? Getting to the Heart of Allopurinol and Febuxostat CV Outcomes
Up in Flames: Antiplatelet Therapy in Patients with Stable Ischemic Heart Disease Receiving Anticoagulation for A-fib
Is Dapagliflozin aDAPtAble to Treating HFrEF in Patients Without Diabetes?
Are Older Adults with Heart Failure Self-Care Aware?
Secondary Stroke Prevention in A-Fib: Do DOACs PROSPER in High-Risk Patients?
Under Pressure: Does Directly Observing Medication Administration Lower Blood Pressure?
Will Oral Semaglutide PIONEER the Way to Lower Cardiovascular Risk?
Using CRP in COPD to Guide Treatment Decisions During Exacerbations
Addressing the Adherence Problem: Do Med Sync Programs Really Work?
Create your
podcast in
minutes
It is Free
The Relaxback UK Show
Good Nurse Bad Nurse
On Call With Dr. Anselm Anyoha
The Doctor’s Farmacy with Mark Hyman, M.D.
The Peter Attia Drive